192 related articles for article (PubMed ID: 8116041)
1. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ.
Tyan DB; Li VA; Czer L; Trento A; Jordan SC
Transplantation; 1994 Feb; 57(4):553-62. PubMed ID: 8116041
[TBL] [Abstract][Full Text] [Related]
2. Intravenous immunoglobulin, HLA allele typing and HLAMatchmaker facilitate successful transplantation in highly sensitized pediatric renal allograft recipients.
Valentini RP; Nehlsen-Cannarella SL; Gruber SA; Mattoo TK; West MS; Lang C; Imam AA
Pediatr Transplant; 2007 Feb; 11(1):77-81. PubMed ID: 17239127
[TBL] [Abstract][Full Text] [Related]
3. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
Lee PC; Ozawa M
Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
[TBL] [Abstract][Full Text] [Related]
4. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients.
Jordan SC; Vo A; Bunnapradist S; Toyoda M; Peng A; Puliyanda D; Kamil E; Tyan D
Transplantation; 2003 Aug; 76(4):631-6. PubMed ID: 12973100
[TBL] [Abstract][Full Text] [Related]
5. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.
Mai ML; Ahsan N; Wadei HM; Genco PV; Geiger XJ; Willingham DL; Taner CB; Hewitt WR; Grewal HP; Nguyen JH; Hughes CB; Gonwa TA
Transplantation; 2009 Jan; 87(2):227-32. PubMed ID: 19155977
[TBL] [Abstract][Full Text] [Related]
6. Management of sensitized patients awaiting renal transplantation: does sequential therapy of intravenous immunoglobulin and simvastatin offer a solution?
Mahmoud KM; Sobh MA; El Shenawy F; Isamil AM; El-Magd MA; Hassan NA; El-Agroudy AE; Sheashaa HA; Opelz G; Ghoneim MA
Eur J Pharmacol; 2007 Apr; 561(1-3):202-5. PubMed ID: 17296177
[TBL] [Abstract][Full Text] [Related]
7. A virtual crossmatch protocol significantly increases access of highly sensitized patients to deceased donor kidney transplantation.
Bingaman AW; Murphey CL; Palma-Vargas J; Wright F
Transplantation; 2008 Dec; 86(12):1864-8. PubMed ID: 19104435
[TBL] [Abstract][Full Text] [Related]
8. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients.
Meng HL; Jin XB; Li XT; Wang HW; Lü JJ
Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial.
Jordan SC; Tyan D; Stablein D; McIntosh M; Rose S; Vo A; Toyoda M; Davis C; Shapiro R; Adey D; Milliner D; Graff R; Steiner R; Ciancio G; Sahney S; Light J
J Am Soc Nephrol; 2004 Dec; 15(12):3256-62. PubMed ID: 15579530
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic strategies in management of the highly HLA-sensitized and ABO-incompatible transplant recipients.
Jordan SC; Peng A; Vo AA
Contrib Nephrol; 2009; 162():13-26. PubMed ID: 19001810
[TBL] [Abstract][Full Text] [Related]
11. Intravenous immunoglobulins and transplantation for patients with anti-HLA antibodies.
Glotz D; Antoine C; Julia P; Pegaz-Fiornet B; Duboust A; Boudjeltia S; Fraoui R; Combes M; Bariety J
Transpl Int; 2004 Jan; 17(1):1-8. PubMed ID: 14685653
[TBL] [Abstract][Full Text] [Related]
12. Histocompatibility testing for highly sensitized transplant candidates.
Saidman SL
Transplant Proc; 2007 Apr; 39(3):673-5. PubMed ID: 17445570
[TBL] [Abstract][Full Text] [Related]
13. Differential inhibitory effects of intravenous immunoglobulin preparations on HLA-alloantibodies in vitro.
Wassmuth R; Hauser IA; Schuler K; Erxleben H; Arnold ML; Koelman CA; Claas FH; Kalden JR
Transplantation; 2001 May; 71(10):1436-42. PubMed ID: 11391232
[TBL] [Abstract][Full Text] [Related]
14. [Histocompatibility tests in a transplantation program].
de-Leo-Cervantes C
Rev Invest Clin; 2005; 57(2):142-6. PubMed ID: 16524052
[TBL] [Abstract][Full Text] [Related]
15. Management of the highly sensitized patient.
Claas FH; Doxiadis II
Curr Opin Immunol; 2009 Oct; 21(5):569-72. PubMed ID: 19682882
[TBL] [Abstract][Full Text] [Related]
16. Desensitization strategies enabling successful renal transplantation in highly sensitized patients.
Beimler JH; Susal C; Zeier M
Clin Transplant; 2006; 20 Suppl 17():7-12. PubMed ID: 17100695
[TBL] [Abstract][Full Text] [Related]
17. Posttransplant immunosuppression in highly sensitized patients.
Akalin E
Contrib Nephrol; 2009; 162():27-34. PubMed ID: 19001811
[TBL] [Abstract][Full Text] [Related]
18. Hyperimmunized patients awaiting cadaveric kidney graft: is there a quick desensitization possible?
Faenza A; Fuga G; Bertelli R; Scolari MP; Buscaroli A; Stefoni S
Transplant Proc; 2008; 40(6):1833-8. PubMed ID: 18675064
[TBL] [Abstract][Full Text] [Related]
19. Low-dose prophylactic intravenous immunoglobulin does not prevent HLA sensitization in left ventricular assist device recipients.
Drakos SG; Kfoury AG; Long JW; Stringham JC; Fuller TC; Nelson KE; Campbell BK; Gilbert EM; Renlund DG
Ann Thorac Surg; 2006 Sep; 82(3):889-93. PubMed ID: 16928502
[TBL] [Abstract][Full Text] [Related]
20. Utility of peritransplant and rescue intravenous immunoglobulin and extracorporeal immunoadsorption in lung transplant recipients sensitized to HLA antigens.
Appel JZ; Hartwig MG; Davis RD; Reinsmoen NL
Hum Immunol; 2005 Apr; 66(4):378-86. PubMed ID: 15866701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
